Genetic Risk of Psychosis in Relation to Cannabis Use: Findings from Polygenic Risk Score Approaches-Journal of Psychiatry and Brain Science-CSCIED科技核心评价数据库-手机版

Genetic Risk of Psychosis in Relation to Cannabis Use: Findings from Polygenic Risk Score Approaches

Genetic Risk of Psychosis in Relation to Cannabis Use: Findings from Polygenic Risk Score Approaches

ES评分 0 浏览量：744 下载量：0

DOI	10.20900/jpbs.20190018
刊名	Journal of Psychiatry and Brain Science JPBS
年，卷(期)	2019, 4(6)
作者	Kristina Adorjan*,Sergi Papiol,
作者单位	1 Institute of Psychiatric Phenomics and Genomics, Medical Center of the University of Munich, Munich, 80336, Germany; 2 Department of Psychiatry and Psychotherapy, Medical Center of the University of Munich, Munich, 80336, Germany
Abstract	A psychotic disorder is a multifactorial phenomenon in which not only environmental influences but also genetic factors play an important role. Evidence indicates that psychotic disorders are characterized by a complex mode of inheritance with high polygenicity, in which a large number of common genetic variants with small effects are relevant. One way to measure this polygenic risk is the calculation of polygenic risk scores (PRS). These reflect the complex multifactorial interaction of coding and regulatory DNA variants in the development of mental illness. It is known that the use of cannabis in patients with schizophrenia (SCZ) is much higher than in the general population. Although an exact clinical prognosis based on PRS is not possible at the present, the results found by PRS investigations so far are quite promising. Initial results suggest that people with SCZ and an increased polygenic risk of schizophrenia are more likely to use cannabis. According to these results, the connection between mental illnesses and cannabis use could therefore not simply be seen as an environmental risk, but rather explained as a gene-environment correlation.
KeyWord	schizophrenia; psychosis; cannabis; genetics; polygenic risk score
基金项目
页码	-

参考文献
相关文献

1.United Nations Office on Drugs and Crime. World Drug Report. New York (US): United Nations on Drugs and Crime; 2016. Available from: https://www.unodc.org/wdr2016/. Accessed 2019 Dec 6.

2.Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry. 2015;72:1235-42.

3.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM–5). Washington, D.C. (US): American Psychiatric Association; 2013.

4.Lovell ME, Bruno R, Johnston J, Matthews A, McGregor I, Allsop DJ, et al. Cognitive, physical, and mental health outcomes between long-term cannabis and tobacco users. Addict Behav. 2018;79:178-88.

5.Kraan T, Velthorst E, Koenders L, Zwaart K, Ising HK, van den Berg D, et al. Cannabis use and transition to psychosis in individuals at ultra-high risk: Review and meta-analysis. Psychol Med. 2015;46(4): 673-81.

6.Linscott RJ, van Os J. An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: On the pathway from proneness to persistence to dimensional expression across mental disorders. Psychol Med. 2013;43(6):1133-49.

7.Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262-9. doi: 10.1093/schbul/sbw003

8.Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319-28.

9.van Os J. Krabbendam L, Myin-Germeys I, Delespaul P. The schizophrenia envirome. Curr Opin Psychiatry. 2005;18(2):141-5.

10.Power RA, Verweij KJ, Zuhair M, Montgomery GW, Henders AK, Heath AC, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry. 2014;19(11):1201-4. doi: 10.1038/mp.2014.51

11.Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, et al. Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review. JAMA Psychiatry. 2016;73(3):292-7.

12.Arseneault L Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212-3.

13.Andréasson S, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet. 1987;2(8574):1483-6.

14.Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325(7374):1199.

15.van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156(4):319-27.

16.Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med. 2003;33(1):15-21.

17.Gage SH, Jones HJ, Burgess S, Bowden J, Davey Smith G, Zammit S, et al. Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. Psychol Med. 2017;47(5):971-80.

18.Zwicker A, Denovan-Wright EM, Uher R. Gene-environment interplay in the etiology of psychosis. Psychol Med. 2018;48(12):1925-36.

19.Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction. 2005;100(5):612-8.

20.Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia. 10-year follow-up after first hospitalization. Am J Psychiatry. 2010;167:987-93.

21.Gill KE, Poe L, Azimov N, Ben-David S, Vadhan NP, Girgis R, et al. Reasons for cannabis use among youths at ultra high risk for psychosis. Early Interv Psychiatry. 2015;9(3):207-10.

22.Hoch E, Friemel CM, Schneider M, editors. Cannabis Expertise. Cannabis: Potenzial und Risiko. Eine wissenschaftliche Bestandsaufnahme. Basel (Switzerland): Springer Verlag; 2018. p.189-213. German.

23.Uliana V, Tomassini A, Pollice R, Gennarelli M, Faravelli F, Casacchia M, et al. Cannabis and psychosis: A systematic review of genetic studies. Curr Psychiat Rev. 2013;9(4):302-15.

24.Ferretjans R, Moreira FA, Teixeira AL, Salgado JV. The endocannabinoid system and its role in schizophrenia: A systematic review of the literature. Braz J Psychiatry. 2012;34(Suppl 2):S163-93.

25.Geoffroy PA, Etain B, Houenou J. Gene × environment interactions in schizophrenia and bipolar disorder: Evidence from neuroimaging. Front Psychiatry. 2013;4:136. doi: 10.3389/fpsyt.2013.00136

26.Henquet C, Rosa A, Krabbendam L, Papiol S, Fananás L, Drukker M, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. 2006;31(12):2748-57.

27.Zondervan KT. Genetic Association Study Design. In: Zeggini E, Morris A, editors. Analysis of Complex Disease Association Studies. Burlington (US): Elsevier; 2011. p. 25-47.

28.Goes FS. Genetics of Bipolar Disorder: Recent Update and Future Directions. Psychiatr Clin North Am. 2016;39(1):139-55. doi: 10.1016/j.psc.2015.10.004

29.Maier RM, Visscher PM, Robinson MR, Wray NR. Embracing polygenicity: a review of methods and tools for psychiatric genetics research. Psychol Med. 2018;48(7):1055-67.

30.Vaucher J, Keating BJ, Lasserre AM, Gan W, Lyall DM, Ward J, et al. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol Psychiatry. 2018;23:1287-92.

31.Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, et al. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia. Nat Neurosci. 2018;21(9):1161–70.

32.Verweij K, Abdellaoui A, Nivard MG, Sainz Cort A, Ligthart L, Draisma HH, et al. Short communication: Genetic association between schizophrenia and cannabis use. Drug Alcohol Depend. 2017;171:117-21. doi: 10.1016/j.drugalcdep.2016.09.022

33.Adorjan K, Lütticke A, Budde M, Heilbronner U, Schulze TG, Papiol S, et al. Polygenic risk burden and cannabis use comorbidity in patients with schizophrenia and bipolar disorder. 2019. Unpublished work.

34.Reginsson GW, Ingason A, Euesden J, Bjornsdottir G, Olafsson S, Sigurdsson E, et al. Polygenic risk scores for schizophrenia and bipolar disorder associate with addiction. Addict Biol. 2018;23(1):485-92. doi: 10.1111/adb.12496

35.Hiemstra M, Nelemans SA, Branje S, van Eijk KR, Hottenga JJ, Vinkers CH, et al. Genetic vulnerability to schizophrenia is associated with cannabis use patterns during adolescence. Drug Alcohol Depend. 2018;190:143-50.

36.Guloksuz S, Pries LK, Delespaul P, Kenis G, Luykx JJ, Lin BD, et al. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry. 2019;18(2):173-82.

引用本文

Kristina Adorjan*,Sergi Papiol. Genetic Risk of Psychosis in Relation to Cannabis Use: Findings from Polygenic Risk Score Approaches, Journal of Psychiatry and Brain Science. 2019; 4; (6). https://doi.org/10.20900/jpbs.20190018.

文献评论

相关学者

相关机构